Logo image of VNDA

VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

NASDAQ:VNDA - US9216591084 - Common Stock

4.64 USD
-0.03 (-0.64%)
Last: 8/27/2025, 4:04:07 PM
4.62 USD
-0.02 (-0.43%)
After Hours: 8/27/2025, 4:04:07 PM
Fundamental Rating

3

Taking everything into account, VNDA scores 3 out of 10 in our fundamental rating. VNDA was compared to 547 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year VNDA has reported negative net income.
In the past year VNDA has reported a negative cash flow from operations.
Of the past 5 years VNDA 4 years were profitable.
Of the past 5 years VNDA 4 years had a positive operating cash flow.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

The Return On Assets of VNDA (-10.71%) is better than 83.00% of its industry peers.
VNDA has a Return On Equity of -13.76%. This is amongst the best in the industry. VNDA outperforms 87.39% of its industry peers.
Industry RankSector Rank
ROA -10.71%
ROE -13.76%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

With an excellent Gross Margin value of 94.40%, VNDA belongs to the best of the industry, outperforming 94.15% of the companies in the same industry.
VNDA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VNDA has been increased compared to 1 year ago.
Compared to 5 years ago, VNDA has more shares outstanding
Compared to 1 year ago, VNDA has a worse debt to assets ratio.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VNDA has an Altman-Z score of 1.00. This is a bad value and indicates that VNDA is not financially healthy and even has some risk of bankruptcy.
VNDA's Altman-Z score of 1.00 is fine compared to the rest of the industry. VNDA outperforms 64.17% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that VNDA is not too dependend on debt financing.
VNDA has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: VNDA outperforms 45.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1
ROIC/WACCN/A
WACC9.73%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 3.25 indicates that VNDA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.25, VNDA is doing worse than 60.69% of the companies in the same industry.
VNDA has a Quick Ratio of 3.23. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
VNDA has a Quick ratio of 3.23. This is comparable to the rest of the industry: VNDA outperforms 41.13% of its industry peers.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 3.23
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -494.74%.
VNDA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.78%.
Measured over the past years, VNDA shows a decrease in Revenue. The Revenue has been decreasing by -2.64% on average per year.
EPS 1Y (TTM)-494.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)11.78%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%4.19%

3.2 Future

VNDA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.83% yearly.
VNDA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.13% yearly.
EPS Next Y-475.88%
EPS Next 2Y-82.36%
EPS Next 3Y6.83%
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y24.69%
Revenue Next 3Y26.56%
Revenue Next 5Y1.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-82.36%
EPS Next 3Y6.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VNDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (8/27/2025, 4:04:07 PM)

After market: 4.62 -0.02 (-0.43%)

4.64

-0.03 (-0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-04 2025-11-04
Inst Owners78.97%
Inst Owner Change1.78%
Ins Owners7.03%
Ins Owner Change4.17%
Market Cap274.18M
Analysts80
Price Target12.92 (178.45%)
Short Float %8.29%
Short Ratio9.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.3%
Min EPS beat(2)-26.44%
Max EPS beat(2)17.84%
EPS beat(4)3
Avg EPS beat(4)15.96%
Min EPS beat(4)-26.44%
Max EPS beat(4)45.98%
EPS beat(8)6
Avg EPS beat(8)5.71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-5.56%
Max Revenue beat(2)8.7%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)8.7%
Revenue beat(8)3
Avg Revenue beat(8)0.35%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-11.88%
EPS NQ rev (3m)-126%
EPS NY rev (1m)-20.98%
EPS NY rev (3m)-20.98%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)-0.54%
Revenue NY rev (1m)-1.21%
Revenue NY rev (3m)-1.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.35
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.73
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS3.44
BVpS8.23
TBVpS6.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.71%
ROE -13.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.4%
FCFM N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.98%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 3.23
Altman-Z 1
F-Score3
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-494.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y-475.88%
EPS Next 2Y-82.36%
EPS Next 3Y6.83%
EPS Next 5YN/A
Revenue 1Y (TTM)11.78%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%4.19%
Revenue Next Year12.81%
Revenue Next 2Y24.69%
Revenue Next 3Y26.56%
Revenue Next 5Y1.13%
EBIT growth 1Y-210.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-263.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.43%
OCF growth 3YN/A
OCF growth 5YN/A